VACCINATION

Strategic Advisory Group

The EAP Vaccination Strategic Advisory Group (VSAG) consists of representatives from all European regions, who are involved in their national immunisation programmes, with the intention to build an effective and interactive network.

Hans Jürgen Dornbusch, MD

Chair

Hans Jürgen Dornbusch, MD

Chair

After completing post-doctoral research as a Rotary Foundation Scholar at the University of California San Diego (1988/89), followed by military service and internship, Dr. Hans Juergen Dornbusch obtained his specialist certification in Paediatrics in 1998 at the University Hospital for Paediatrics and Adolescent Medicine in Graz. He also sub-specialized in paediatric haematology/oncology, with a strong clinical and research focus on infectious diseases.

 

Dr. Dornbusch is the author and co-author of numerous scientific publications and has held a teaching position in paediatric infectious diseases at the Medical University of Graz since 2004. He is a frequent lecturer, particularly in postgraduate training on infectious diseases and vaccinology, and has been practising as a primary care paediatrician since 2006. In 2009, he completed his habilitation on “Diagnostic markers for early detection of infectious complications in immunocompromised children and adolescents.”

 

He currently holds leading vaccine-related roles, including Head of the Vaccination Board of the Austrian Society for Paediatrics and Adolescent Medicine and Chairman of the Vaccination Strategic Advisory Group of the European Academy of Paediatrics (EAP).

ABOUT

VACCINATION

The major goal of the EAP VSAG is to support activities leading to better Harmonisation of Vaccination programmes within the European region and to optimal Coverage with recommended vaccines.


The EAP VSAG meets twice a year for discussion of the current situation of immunisation in Europe. Data are collected mainly by means of surveys. Major topics comprise implementation of recommended vaccines, national monitoring of vaccination coverage, measures to increase vaccination coverage, approach to vaccine refusal / “individualization”, shortages in vaccine supply, and others.


The EAP VSAG seeks collaboration with WHO, ECDC, EPA and other European organizations interested in the field of Vaccinology, in order to optimize its efforts to achieve the goals mentioned above.


The EAP VSAG supports the ambitious WHO European Vaccine Action Plan 2015-2020 with its vision: A European Region free of vaccine-preventable diseases, where all countries provide equitable access to high-quality, safe, affordable vaccines and immunization services throughout the life course.

Agendas

Documents

A Symposium on Prevention of Meningococcal Disease
Influenza – The Austrian Experience

Other Documents

Outbreaks in Portugal – I Esteves Vilamoura 12 05 2017

Minutes

Spring

2020
2019
2018
2017
2016
2015
2014
2013
2012

Winter

2019
2018
2017
2016
2015
2014
2013
close menu icon

Your Enquiries Are Welcome

We will respond to you by Email

""
 

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative:

  • BERTHOLD KOLETZKO
Read more